Ribomic Overview
Ribomic (4591.T) has a ROE of -43.34%, above the Healthcare sector average of -75.59%.
Get informed when a big investor buys or sells
+ Follow-43.34%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Ribomic (4591.T) currently reports a ROE of -43.34%. That is above the Healthcare sector average of -75.59%. Use the charts on this page to explore Ribomic's ROE history and peer comparisons.
Ribomic's ROE of -43.34% is higher than the Healthcare sector average of -75.59%. That is roughly 42.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Ribomic's current -43.34% should be judged against Healthcare norms (sector average: -75.59%) and against 4591.T's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -43.34%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.59%. From there, open related valuation or income-statement pages for Ribomic, and consider following 4591.T for alerts when major investors trade the stock.
Ribomic is classified in the Healthcare sector. On ROE, it currently shows -43.34% versus a sector average near -75.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 4591.T with unrelated industries.
